Trade GlaxoSmithKline PLC - GSKl CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.070 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023925% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002007% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | GBP | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United Kingdom of Great Britain and Northern Ireland | ||||||||
| Commission on trade | 0% |
| Prev. Close | 13 |
| Open | 13.07 |
| 1-Year Change | -7.04% |
| Day's Range | 13.01 - 13.13 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 20, 2024 | 13.000 | 0.010 | 0.08% | 12.990 | 13.080 | 12.975 |
| Nov 19, 2024 | 13.030 | -0.140 | -1.06% | 13.170 | 13.195 | 12.930 |
| Nov 18, 2024 | 13.070 | -0.045 | -0.34% | 13.115 | 13.180 | 12.975 |
| Nov 15, 2024 | 13.040 | 0.170 | 1.32% | 12.870 | 13.235 | 12.800 |
| Nov 14, 2024 | 13.525 | 0.015 | 0.11% | 13.510 | 13.610 | 13.415 |
| Nov 13, 2024 | 13.625 | 0.005 | 0.04% | 13.620 | 13.745 | 13.505 |
| Nov 12, 2024 | 13.705 | -0.045 | -0.33% | 13.750 | 13.785 | 13.510 |
| Nov 11, 2024 | 13.985 | 0.165 | 1.19% | 13.820 | 14.055 | 13.800 |
| Nov 8, 2024 | 13.810 | -0.135 | -0.97% | 13.945 | 13.960 | 13.650 |
| Nov 7, 2024 | 13.810 | 0.145 | 1.06% | 13.665 | 13.825 | 13.665 |
| Nov 6, 2024 | 13.720 | -0.235 | -1.68% | 13.955 | 14.140 | 13.665 |
| Nov 5, 2024 | 13.895 | -0.150 | -1.07% | 14.045 | 14.125 | 13.850 |
| Nov 4, 2024 | 14.135 | 0.310 | 2.24% | 13.825 | 14.190 | 13.825 |
| Nov 1, 2024 | 14.160 | 0.045 | 0.32% | 14.115 | 14.335 | 13.960 |
| Oct 31, 2024 | 13.980 | 0.095 | 0.68% | 13.885 | 13.995 | 13.710 |
| Oct 30, 2024 | 14.060 | -0.205 | -1.44% | 14.265 | 14.485 | 13.805 |
| Oct 29, 2024 | 14.495 | 0.060 | 0.42% | 14.435 | 14.600 | 14.435 |
| Oct 28, 2024 | 14.435 | 0.115 | 0.80% | 14.320 | 14.540 | 14.295 |
| Oct 25, 2024 | 14.480 | 0.030 | 0.21% | 14.450 | 14.510 | 14.330 |
| Oct 24, 2024 | 14.500 | -0.055 | -0.38% | 14.555 | 14.605 | 14.475 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
GSK Company profile
GlaxoSmithKline PLC - GSK CFD
GlaxoSmithKline (GSK) is a global healthcare company focussed in pharmaceuticals, vaccine development and consumer healthcare products.
The company began as an apothecary shop in London in 1715. Today, GlaxoSmithKline is headquartered in Brentford, England, with regional offices in the US and Singapore. GlaxoSmithKline’s primary listing is on the London Stock Exchange under the ticker symbol ‘GSK’. The GSK stock price in the form of American depositary shares is listed on the New York Stock Exchange.
GlaxoSmithKline’s pharmaceutical business covers a broad portfolio of medicines in respiratory, HIV, immuno-inflammation and oncology. The company has a leadership position in respiratory disease medicines. GlaxoSmithKline’s HIV business is managed through its unit ViiV Healthcare, with Pfizer and Shionogi as minority shareholders.
In addition to respiratory and HIV treatments, the company has a portfolio of pharmaceutical products for the treatment of conditions such as lupus, urology and anti-infectives.
Its Established Products Portfolio (EPP) includes mature medicines in the areas of anti-infectives, allergy, central nervous system, dermatology, respiratory and urology. These products are an important part of our Emerging Markets business.
GlaxoSmithKline is actively researching the World Health Organisation’s three priority diseases - HIV/AIDS, tuberculosis and malaria.
GlaxoSmithKline is also one of the world’s largest vaccine companies with a portfolio of more than 20 vaccines. The company has 12 vaccine manufacturing sites around the world. One of its four global R&D centres is dedicated to mRNA technology.
GlaxoSmithKline’s consumer healthcare business has portfolio of brands that include Sensodyne, Parodontax, Polident, Advil, Voltaire, Panadol, Striven, Theraflu and Centrum across oral health, pain relief, cold, flu and allergy, digestive health, and vitamins, mineral and supplements segments. GlaxoSmithKline is set to spin-off its consumer healthcare business into an independent company under the name ‘Haleon’.’
The company pays dividends on a quarterly basis, in July, October, January and April.
Follow the GlaxoSmithKline stock price live at Capital.com today.
| Industry: | Pharmaceuticals (NEC) |
980 Great West Road
BRENTFORD
MIDDLESEX TW8 9GS
GB
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com